148 related articles for article (PubMed ID: 15179666)
61. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
62. The effects of novel antipsychotics on glucose and lipid levels.
Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
[TBL] [Abstract][Full Text] [Related]
63. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Melnik T; Soares BG; Puga ME; Atallah AN
Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
[TBL] [Abstract][Full Text] [Related]
64. [Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].
Birkás Kováts D; Palik E; Faludi G; Cseh K
Neuropsychopharmacol Hung; 2005 Sep; 7(3):132-9. PubMed ID: 16493877
[TBL] [Abstract][Full Text] [Related]
65. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.
Gupta S; Steinmeyer C; Frank B; Madhusoodanan S; Lockwood K; Lentz B; Keller P
Am J Ther; 2003; 10(5):348-55. PubMed ID: 12975719
[TBL] [Abstract][Full Text] [Related]
66. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
67. A typical mood stabilizers: a "typical role for atypical antipsychotics.
Malhi GS; Berk M; Bourin M; Ivanovski B; Dodd S; Lagopoulos J; Mitchell PB
Acta Psychiatr Scand Suppl; 2005; (426):29-38. PubMed ID: 16104066
[TBL] [Abstract][Full Text] [Related]
68. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
69. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Cohen D; Correll CU
J Clin Psychiatry; 2009 May; 70(5):765-6. PubMed ID: 19552870
[No Abstract] [Full Text] [Related]
70. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Mosolov SN; Kabanov SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
[No Abstract] [Full Text] [Related]
71. Atypical antipsychotics and diabetes mellitus: an association.
Liberty IF; Todder D; Umansky R; Harman-Boehm I
Isr Med Assoc J; 2004 May; 6(5):276-9. PubMed ID: 15151366
[TBL] [Abstract][Full Text] [Related]
72. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.
Oerther S; Ahlenius S
J Pharmacol Exp Ther; 2000 Feb; 292(2):731-6. PubMed ID: 10640312
[TBL] [Abstract][Full Text] [Related]
73. Diabetes mellitus during olanzapine and quetiapine treatment in Japan.
Cohen D
J Clin Psychiatry; 2005 Feb; 66(2):265-6; author reply 266-7. PubMed ID: 15705015
[No Abstract] [Full Text] [Related]
74. Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Connolly JG; Toomey TJ; Schneeweiss MC
Psychiatr Serv; 2015 Jun; 66(6):604-9. PubMed ID: 25726977
[TBL] [Abstract][Full Text] [Related]
75. Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.
Guha P; Roy K; Sanyal D; Dasgupta T; Bhattacharya K
J Indian Med Assoc; 2005 Dec; 103(12):660-4. PubMed ID: 16821658
[TBL] [Abstract][Full Text] [Related]
76. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.
Nasrallah HA; Newcomer JW
J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S7-14. PubMed ID: 15356415
[TBL] [Abstract][Full Text] [Related]
77. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.
Henderson DC; Cagliero E; Copeland PM; Louie PM; Borba CP; Fan X; Freudenreich O; Goff DC
J Clin Psychiatry; 2007 Apr; 68(4):533-41. PubMed ID: 17474808
[TBL] [Abstract][Full Text] [Related]
78. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?
Henderson DC
CNS Drugs; 2002; 16(2):77-89. PubMed ID: 11825099
[TBL] [Abstract][Full Text] [Related]
79. [Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics].
De Nayer A; De Hert M; Scheen A; Van Gaal L; Peuskens J
Encephale; 2007; 33(2):197-202. PubMed ID: 17675915
[TBL] [Abstract][Full Text] [Related]
80. Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.
Bailey RK
J Natl Med Assoc; 2003 Feb; 95(2):137-44. PubMed ID: 12760609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
